 Many anti-inflammatory biological mediators, such as infliximab, etanercept, and anakinra are being tried, but there are no randomized controlled trials demonstrating effectiveness.In mild disease, patients present with eyelid retraction.In fact, upper eyelid retraction is the most common ocular sign of Graves' orbitopathy.